Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?

Executive Summary

Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference: Alder's Options for CGRP drug; CRISPR's not worried about Cas9 controversy; Theratechnologies seeks more HIV niche products; Moderna is shaping up to have a big 2018; TG Therapeutics and Immunomedics milestones ahead.

Advertisement

Related Content

10 First Approvals To Look Out For In 2018
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Confidence Builds For Theratechnologies' Game-Changing HIV Monoclonal
AZ Makes Fresh mRNA Move With Ethris Respiratory Pact
CRISPR Therapeutics President Sam Kulkarni On Business Development
TG Celebrates High Risk CLL Data - But Cloud Looms From Rival Trial
Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel